Albiglutide

Summary

Albiglutide (CHEMBL2107841) is an approved protein (ATC A10BJ04) targeting GLP1R; indicated across 4 conditions including diabetes mellitus and type 2 diabetes mellitus.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Protein
• ATC class: A10BJ04
• Targets: 1 (GLP1R)
• Indications: 4 conditions
• Clinical trials: 30

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2107841
Name	Albiglutide
Type	Protein
Max phase	4
ATC	A10BJ04

Also known as: Albiglutida, Albiglutide, Albiglutide (genetical recombination), Eperzan, GSK-716155, GSK716155, Tanzeum, ALBIGLUTIDE

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
GLP1R	GLP-1 receptor	Agonist	7.7	0.2%	P43220

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

Aggregated over 1 target gene(s): GLP1R.

Top Reactome pathways

3 total, by targets touching each:

Pathway	Targets	Genes
Glucagon-like Peptide-1 (GLP1) regulates insulin secretion	1	GLP1R
G alpha (s) signalling events	1	GLP1R
Glucagon-type ligand receptors	1	GLP1R

Dominant GO biological processes

GO term	Targets
cell surface receptor signaling pathway	1
adenylate cyclase-activating G protein-coupled receptor signaling pathway	1
activation of adenylate cyclase activity	1
positive regulation of cytosolic calcium ion concentration	1
learning or memory	1
regulation of heart contraction	1
post-translational protein targeting to membrane, translocation	1
negative regulation of blood pressure	1
positive regulation of blood pressure	1
hormone secretion	1
response to psychosocial stress	1
signal transduction	1
G protein-coupled receptor signaling pathway	1
regulation of biological quality	1
cellular response to glucagon stimulus	1

Indications & clinical

Indications

4 indications (2 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
diabetes mellitus	4	MONDO:0005015	EFO:0000400
type 2 diabetes mellitus	4	MONDO:0005148	MONDO:0005148
congestive heart failure	2	MONDO:0005009	EFO:0000373
type 1 diabetes mellitus	2	MONDO:0005147	MONDO:0005147

Clinical trials

Total trials: 30.

Phase distribution

Phase	Trials
PHASE3	13
PHASE2	6
PHASE1	6
PHASE4	5

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02465515	PHASE4	COMPLETED	Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Subjects With Type 2 Diabetes Mellitus
NCT02496221	PHASE4	COMPLETED	A Study Evaluating the Effect of Albiglutide on Gallbladder Emptying in Healthy Subjects
NCT02750930	PHASE4	TERMINATED	Extension to Study 200952 to Evaluate the Long-term Safety, Tolerability and Pharmacodynamics of Albiglutide Liquid Drug Product in Type 2 Diabetes Mellitus Subjects
NCT02793154	PHASE4	TERMINATED	An Exploratory Study on the Effects of Repeat Doses of Albiglutide Compared to Exenatide on Gastric Myoelectrical Activity and Gastric Emptying in Type 2 Diabetes Mellitus Subjects
NCT02802514	PHASE4	TERMINATED	A Study Comparing the Effect of Albiglutide With Exenatide on Regional Brain Activity Related to Nausea in Healthy Subjects
NCT00838903	PHASE3	COMPLETED	Efficacy and Safety of Albiglutide in Treatment of Type 2 Diabetes
NCT00838916	PHASE3	COMPLETED	A Study to Determine the Safety and Efficacy of Albiglutide in Patients With Type 2 Diabetes
NCT00839527	PHASE3	COMPLETED	A Study to Determine the Safety and Efficacy of Albiglutide in Subjects With Type 2 Diabetes
NCT00849017	PHASE3	COMPLETED	Safety and Efficacy Study of Albiglutide in Type 2 Diabetes
NCT00849056	PHASE3	COMPLETED	Safety and Efficacy of Albiglutide in Type 2 Diabetes
NCT00976391	PHASE3	COMPLETED	A Study to Determine the Safety and Efficacy of Albiglutide Administered in Combination With Insulin Glargine
NCT01098539	PHASE3	COMPLETED	A Study of the Efficacy and Safety of Albiglutide in Subjects With Type 2 Diabetes With Renal Impairment.
NCT01128894	PHASE3	COMPLETED	A Study to Determine the Efficacy and Safety of Albiglutide as Compared With Liraglutide.
NCT01777282	PHASE3	COMPLETED	A Study to Determine the Long Term Safety and Efficacy of Albiglutide in Combination With Oral Monotherapy Antihyperglycemic Medications in Japanese Patients With Type 2 Diabetes Mellitus
NCT02229227	PHASE3	COMPLETED	Safety and Efficacy of Albiglutide + Insulin Glargine Versus Insulin Lispro + Insulin Glargine Subjects With Type 2 Diabetes Mellitus
NCT02229240	PHASE3	WITHDRAWN	Albiglutide Versus Placebo Added-on to Basal-Bolus Insulin Therapy in Subjects With Type 2 Diabetes Mellitus
NCT02787551	PHASE3	COMPLETED	Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period
NCT03015519	PHASE3	WITHDRAWN	A Study to Evaluate Pharmacokinetics, Safety and Efficacy of Albiglutide in Pediatric Subjects With Type 2 Diabetes Mellitus
NCT00354536	PHASE2	COMPLETED	In-patient Study With GSK716155 In Patients With Type 2 Diabetes Mellitus
NCT00518115	PHASE2	COMPLETED	Out-Patient Study in Patients With Type 2 Diabetes Mellitus Who Are Taking no Diabetes Medication or Metformin Only
NCT01098461	PHASE2	COMPLETED	Dose Ranging Study of Albiglutide in Japanese Subjects
NCT01357850	PHASE2	COMPLETED	A Multi-center, Placebo-controlled Study to Evaluate the Safety of GSK716155 and Its Effects on Myocardial Metabolism, Myocardial Function, and Exercise Capacity in Patients With NYHA Class II/III Congestive Heart Failure
NCT01357889	PHASE2	COMPLETED	Pharmacokinetics/Pharmacodynamics of Albiglutide
NCT01475734	PHASE2	COMPLETED	Albiglutide Glucose Clamp Study in Subjects With Type 2 Diabetes
NCT00394030	PHASE1	COMPLETED	Injection Site Study In Patients With Type 2 Diabetes Mellitus (T2DM) And Healthy Volunteers
NCT00530309	PHASE1	COMPLETED	Clinical Assessment of GSK716155 for Type 2 Diabetes Mellitus
NCT00537719	PHASE1	COMPLETED	Scintigraphy Study to Assess Gastric Emptying in Healthy Subjects Given GSK716155 or Placebo.
NCT00938158	PHASE1	COMPLETED	A Study of the Pharmacokinetics of Albiglutide in Normal and Renally Impaired Subjects.
NCT01077505	PHASE1	COMPLETED	An Evaluation of the Pharmacokinetics of an Oral Contraceptive (Brevicon) When Co-administered With Albiglutide .
NCT01406262	PHASE1	COMPLETED	Albiglutide Thorough ECG Study in Healthy Volunteers

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

18 molecules share ≥1 primary target. Top 18 by shared-target count:

Molecule	Source	Status	Shared targets
LIRAGLUTIDE	ChEMBL + PubChem	Phase 4 (approved)	GLP1R
DIHYDROERGOTAMINE	ChEMBL	Phase 4 (approved)	GLP1R
ELAGOLIX	ChEMBL	Phase 4 (approved)	GLP1R
EXENATIDE	ChEMBL	Phase 4 (approved)	GLP1R
GLUCAGON	ChEMBL	Phase 4 (approved)	GLP1R
LOPERAMIDE	ChEMBL	Phase 4 (approved)	GLP1R
PERPHENAZINE	ChEMBL	Phase 4 (approved)	GLP1R
SECRETIN	ChEMBL	Phase 4 (approved)	GLP1R
SEMAGLUTIDE	ChEMBL	Phase 4 (approved)	GLP1R
TIRZEPATIDE	ChEMBL	Phase 4 (approved)	GLP1R
TOLVAPTAN	ChEMBL	Phase 4 (approved)	GLP1R
ORFORGLIPRON	ChEMBL	Phase 3	GLP1R
COTADUTIDE	ChEMBL	Phase 2	GLP1R
DANUGLIPRON	ChEMBL	Phase 2	GLP1R
DEVAZEPIDE	ChEMBL	Phase 2	GLP1R
GLP-1	ChEMBL	Phase 2	GLP1R
LOTIGLIPRON	ChEMBL	Phase 2	GLP1R
PF-06291874	ChEMBL	Phase 2	GLP1R